Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Potential cure for lymphoma in HIV patients

10.01.2005


Stem cell transplants have become the standard of care for Patients with relapsed lymphoma, but not for Patients who suffer from both this disease and HIV. A new study showing that this treatment is a viable option for select Patients with HIV-associated lymphoma will be published in the January 15, 2005, issue of Blood, the official journal of the American Society of Hematology.



Because of the immunodeficiency associated with HIV, HIV-positive Patients are more likely to develop lymphoma than HIV-negative individuals, and the treatment for their cancer is far less likely to be successful.

Sonali Smith, M.D., Assistant Professor of Medicine at the University of Chicago notes, "The treatment of malignant lymphomas in HIV-infected individuals remains challenging, due to both the high incidence of refractory disease and the high risk of treatment-related complications. The ability of high dose chemotherapy as demonstrated in this pilot study to effectively treat even refractory disease is highly encouraging and certainly warrants further study."


Researchers from the City of Hope Cancer Center studied 20 Patients (aged 11 to 68) who had HIV and lymphoma, either Hodgkin’s or non-Hodgkin’s. The selected Patients had undergone previous standard-dose frontline chemotherapy for their lymphoma, but the majority either failed to achieve a complete remission or had relapsed after an initial remission. The median length of study follow-up was approximately two and a half years, with a range of about six months to six years.

All study Patients were to undergo autologous stem cell rescue. In an autologous transplant, stem cells are removed from the patient and frozen for later use. The patient receives high-dose chemotherapy to kill any lymphoma in the body, and the autologous stem cells are then infused back into the patient to repopulate the bone marrow wiped out by the chemotherapy.

Before the transplant, Patients were given one of two conditioning regimens, either high dose chemotherapy alone or in combination with radiation therapy, to destroy the cancerous cells. Most (17 Patients versus three) received the chemotherapy-only option. Radiation therapy was selected for Patients younger than 55 who had poorer prognostic factors: either the cancer had spread to multiple lymph nodes or the patient had bulky disease (indicated by a cancerous mass greater than 5 – 10 cm).

Reversible abnormalities in liver function, a side effect of the intensive treatment, were experienced in a majority of the Patients. One patient, the oldest in the study, developed cardiomyopathy (a weakening of the heart) and kidney failure due to treatment toxicities and died a few weeks after the transplant. Opportunistic infections, such as herpes zoster and cytomegalovirus infection, also occurred in a few Patients after the transplant, but were managed with appropriate therapy.

Throughout the study, all Patients were to receive highly active antiretroviral therapy (HAART) to help reduce these opportunistic infections and improve immunodeficiency, however, only nine Patients were able to tolerate this treatment for the entire study due to side effects such as nausea and inflammation of the mouth lining. The majority of Patients, though, did resume the HAART therapy soon after discharge from the hospital.

Although two Patients died of relapsed lymphoma a few months after transplant, 17 of the 20 Patients (85 percent) are currently alive and in remission. In addition, the underlying HIV infection did not worsen as a result of the transplant and associated treatments.

"The results of this study are significant because, despite the use of effective antiviral drugs such as HAART, lymphoma is still a major cause of suffering and death in HIV-infected individuals. It’s important to know that stem cell transplant is an available and highly successful treatment option for these Patients," said Amrita Krishnan, M.D., a staff physician at the City of Hope Cancer Center and lead author of the study.

Laura Stark | EurekAlert!
Further information:
http://www.hematology.org

More articles from Life Sciences:

nachricht Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View
22.06.2018 | University of Sussex

nachricht New cellular pathway helps explain how inflammation leads to artery disease
22.06.2018 | Cedars-Sinai Medical Center

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>